Eudaimonia Partners’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q1
$565K Sell
726
-58
-7% -$41.3K 0.13% 147
2023
Q4
$457K Sell
784
-1,154
-60% -$674K 0.12% 149
2023
Q3
$1.04M Sell
1,938
-89
-4% -$45.9K 0.25% 90
2023
Q2
$951K Buy
2,027
+37
+2% +$15.5K 0.21% 114
2023
Q1
$684K Sell
1,990
-151
-7% -$50.9K 0.16% 138
2022
Q4
$783K Buy
2,141
+57
+3% +$20.2K 0.19% 127
2022
Q3
$674K Sell
2,084
-2,034
-49% -$644K 0.18% 131
2022
Q2
$1.33M Sell
4,118
-281
-6% -$84.3K 0.25% 105
2022
Q1
$1.26M Buy
+4,399
New +$1.13M 0.21% 126
2021
Q3
$826K Sell
3,576
-2
-0.1% -$494 0.15% 166
2021
Q2
$821K Sell
3,578
-77
-2% -$15.5K 0.15% 162
2021
Q1
$683K Buy
3,655
+7
+0.2% +$1.37K 0.14% 165
2020
Q4
$616K Sell
3,648
-44
-1% -$6.57K 0.14% 167
2020
Q3
$546K Buy
3,692
+772
+26% +$119K 0.14% 158
2020
Q2
$479K Sell
2,920
-100
-3% -$15.3K 0.18% 131
2020
Q1
$419K Sell
3,020
-443
-13% -$60.9K 0.18% 133
2019
Q4
$455K Buy
+3,463
New +$401K 0.18% 134

Other funds holding LLY

Eudaimonia Partners's LLY Position: Q1 2024 in Review

Eudaimonia Partners reduced its Eli Lilly (LLY) stake by 7.4% in Q1 2024, selling an estimated $41.3K and leaving 726 shares worth $565K. The position accounts for 0.13% of the portfolio, ranked #147.

Eudaimonia Partners first reported a position in LLY in Q4 2019 and has held it in 17 quarters since. The position peaked at $1.33M in Q2 2022. 3,460 funds tracked by Wall St. Rank hold LLY as of Q1 2024.

  • Eudaimonia Partners held 726 shares of Eli Lilly worth $565K as of Q1 2024.
  • Eudaimonia Partners sold 58 Eli Lilly shares in Q1 2024, an estimated $41.3K.
  • Eli Lilly made up 0.13% of Eudaimonia Partners's portfolio in Q1 2024, its #147 holding.
  • Eudaimonia Partners first reported a position in Eli Lilly in Q4 2019 and has held it in 17 quarters since.
  • Eudaimonia Partners's Eli Lilly position peaked at $1.33M in Q2 2022.
  • 3,460 funds tracked by Wall St. Rank held Eli Lilly as of Q1 2024.

Based on Eudaimonia Partners's 13F filing for Q1 2024, filed 25 Apr 2024.